The in vitro metabolism of GMDTC in liver microsomes of human, monkey, dog, rat and mouse: Metabolic stability assessment, metabolite identification and interspecies comparison

被引:1
|
作者
Hu, Wei [1 ]
Zhong, Zhi-Yong [2 ]
Ren, Xue-Feng [2 ]
Liu, Hai-Yang [1 ]
Tang, Xiao-Jiang [1 ,2 ,3 ,4 ]
机构
[1] South China Univ Technol, Sch Chem & Chem Engn, Key Lab Funct Mol Engn Guangdong Prov, Guangzhou 510641, Peoples R China
[2] Jianersheng Zhuhai Pharmtech Co Ltd, Zhuhai 519040, Peoples R China
[3] Hunan Prevent & Treatment Inst Occupat Dis, Changsha 410021, Hunan, Peoples R China
[4] Southern Med Univ, Guangzhou 510515, Peoples R China
基金
中国国家自然科学基金;
关键词
GMDTC; Metabolic stability; Metabolite identification; Liver microsomes; Interspecies differences; CADMIUM;
D O I
10.1016/j.jpba.2023.115718
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Sodium (S)- 2-(dithiocarboxylato((2 S,3 R,4 R,5 R)- 2,3,4,5,6-pentahydroxyhexyl)amino)- 4(methylthio) butanoate (GMDTC) is a compound that removes cadmium from kidney cells. This study aims to investigate the metabolic stability and metabolite identification of GMDTC in various liver microsomes, including those from human, monkey, dog, rat and mouse. The results show that the T-1/2 values of GMDTC in human, monkey, dog, rat and mouse liver microsomes were 16.54, 18.14, 16.58, 15.16 and 16.00 min, respectively. While the hepatic extraction ratios (ERh) of GMDTC measured after 60 min incubation in these liver microsomes were 0.82, 0.70, 0.80, 0.75 and 0.79, respectively, indicating that GMDTC exhibits rapid hepatic metabolism and high hepatic clearance with no significant interspecies differences. Subsequent metabolite identification by high-resolution mass spectrometry revealed the presence of three metabolites, designated M1 similar to M3. The major metabolite products of GMDTC were found to be M1 and M2. The relative abundances of the hydrolysis products (M1 and M2) in human, monkey, dog, rat and mouse liver microsomes were found to be 97.18%, 97.99%, 95.94%, 96.31% and 93.43%, respectively, indicating that hydrolysis is the primary metabolic pathway of GMDTC in liver microsomes in vitro, and with no significant interspecies differences.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] In vitro hepatic conversion of the anticancer agent nemorubicin to its active metabolite PNU-159682 in mice, rats and dogs: A comparison with human liver microsomes
    Quintieri, Luigi
    Fantin, Marianna
    Palatini, Pietro
    De Martin, Sara
    Rosato, Antonio
    Caruso, Michele
    Geroni, Cristina
    Floreani, Maura
    BIOCHEMICAL PHARMACOLOGY, 2008, 76 (06) : 784 - 795
  • [42] An UPLC-ESI-MS/MS Bioanalytical Methodology for the Quantification of Gilteritinib in Human Liver Microsomes: Application to In Vitro and In Silico Metabolic Stability Estimation
    Attwa, Mohamed W.
    AlRabiah, Haitham
    Alsibaee, Aishah M.
    Abdelhameed, Ali S.
    Kadi, Adnan A.
    SEPARATIONS, 2023, 10 (05)
  • [43] Development and Validation of a Rapid LC-MS/MS Method for Quantifying Alvocidib: In Silico and In Vitro Metabolic Stability Estimation in Human Liver Microsomes
    Attwa, Mohamed W.
    AlRabiah, Haitham
    Kadi, Adnan A.
    MOLECULES, 2023, 28 (05):
  • [44] METABOLISM OF FK506, A POTENT IMMUNOSUPPRESSIVE AGENT, BY CYTOCHROME-P450 3A ENZYMES IN RAT, DOG AND HUMAN LIVER-MICROSOMES
    SHIRAGA, T
    MATSUDA, H
    NAGASE, K
    IWASAKI, K
    NODA, K
    YAMAZAKI, H
    SHIMADA, T
    FUNAE, Y
    BIOCHEMICAL PHARMACOLOGY, 1994, 47 (04) : 727 - 735
  • [45] Development of a Fast and Sensitive UPLC-MS/MS Analytical Methodology for Fenebrutinib Estimation in Human Liver Microsomes: In Vitro and In Silico Metabolic Stability Evaluation
    Attwa, Mohamed W.
    Alsibaee, Aishah M.
    Aljohar, Haya I.
    Abdelhameed, Ali S.
    Kadi, Adnan A.
    SEPARATIONS, 2023, 10 (05)
  • [46] Pharmacokinetic study in pigs and in vitro metabolic characterization in pig- and human-liver microsomes reveal marked differences in disposition and metabolism of tiletamine and zolazepam (Telazol)
    Kumar, Atul
    Mann, Henry J.
    Remmel, Rory P.
    Beilman, Greg J.
    Kaila, Nitin
    XENOBIOTICA, 2014, 44 (04) : 379 - 390
  • [47] Metabolism of the new nonbenzodiazepine anxiolytic agent, RWJ-51204, in mouse, rat, dog, monkey and human hepatic S9 fractions, and in rats, dogs and humans
    W. N. Wu
    L. A. McKown
    A. B. Reitz
    European Journal of Drug Metabolism and Pharmacokinetics, 2004, 29 : 263 - 268
  • [48] Metabolism of the new nonbenzodiazepine anxiolytic agent, RWJ-51204, in mouse, rat, dog, monkey and human hepatic S9 fractions, and in rats, dogs and humans
    Wu, WN
    McKown, LA
    Reitz, AB
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2004, 29 (04) : 263 - 268
  • [49] An ultra-fast validated green UPLC-MS/MS method for the quantification of osimertinib in human liver microsomes: Screening for ADME parameters and in vitro metabolic stability
    Attwa, Mohamed W.
    Abdelhameed, Ali S.
    Kadi, Adnan A.
    ACTA CHROMATOGRAPHICA, 2025,
  • [50] Identification and cross-species comparison of in vitro phase I brevetoxin (BTX-2) metabolites in northern Gulf of Mexico fish and human liver microsomes by UHPLC-HRMS(/MS)
    Gwinn, Jessica Kay
    Robertson, Alison
    Ivanova, Lada
    Faeste, Christiane Kruse
    Kryuchkov, Fedor
    Uhlig, Silvio
    TOXICON-X, 2023, 19